Gelteq (GELS) Debt to Equity (2023 - 2025)

Gelteq (GELS) recorded quarterly Debt to Equity of $0.27 in Q2 2025, up 4.92% quarter-over-quarter from $0.25 in Q2 2024, and up 4.92% on a YoY basis from $0.25 in Q2 2024.

Gelteq (GELS) Debt to Equity (2023 - 2025) Analysis & Trends

Gelteq's Debt to Equity history runs 3 years deep, the most recent figure standing at $0.27 for Q2 2025.

  • In Q2 2025, Debt to Equity rose 4.92% year-over-year to $0.27; the TTM figure through Jun 2025 stood at $0.27 (up 4.92% YoY), while the FY2025 annual figure was $0.27, up 4.92% from the prior year.
  • Debt to Equity was $0.27 for Q2 2025 at Gelteq, up from $0.25 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.27 in Q2 2025 to a low of $0.13 in Q2 2023.
  • Historically, Debt to Equity has averaged $0.22 across 3 years, with a median of $0.25 in 2024.
  • The sharpest annual moves came in 2024 and 2025: Debt to Equity jumped 91.61% in 2024, then grew 4.92% in 2025.
  • A 3-year view of Debt to Equity shows it stood at $0.13 in 2023, then surged by 91.61% to $0.25 in 2024, then gained by 4.92% to $0.27 in 2025.
  • The last three Debt to Equity figures came in at $0.27 (Q2 2025), $0.25 (Q2 2024), and $0.13 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 2.02
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 2.80
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 0.01
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 0.61
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 0.86
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 0.47
10 Gelteq 10.57 Mn 10.34 Mn - 0.27

Historic Data

Download Data
DateValue
Jun 30, 2025 0.27
Jun 30, 2024 0.25
Jun 30, 2023 0.13